Mingde Biotech: The company's stock trading may be subject to delisting risk warning.

Mingde Biotechnology announced that it is expected that the total profit, net profit, and net profit after deducting non-recurring gains and losses for the audited 2025 fiscal year will be negative, and the deducted operating income will be less than 300 million yuan. The company expects a total loss of 50 to 75 million yuan for the 2025 fiscal year, with a net profit attributable to shareholders of listed companies of 15 to 25 million yuan and a net profit after deducting non-recurring gains and losses attributable to shareholders of listed companies of 100 to 140 million yuan. The expected operating income is 250 to 310 million yuan, with deducted operating income of 237 to 297 million yuan. According to Article 9.3.1 of the Shenzhen Stock Exchange Stock Listing Rules, the company's stock trading may be subject to delisting risk warnings by the Shenzhen Stock Exchange after the disclosure of the 2025 annual report.